BioNTech SE
Business
BioNTech SE is a global next-generation immunotherapy company developing and commercializing novel medicines that harness the immune system to treat cancer, infectious diseases and other serious diseases. It offers mRNA-based immunotherapies and vaccines, protein-based therapeutics including monoclonal and bispecific antibodies and ADCs, cell therapies (including CAR‑T and neoantigen-targeted T‑cell products), and related manufacturing and computational/AI capabilities. Its business is organized around oncology and infectious‑disease pipelines, supported by GMP manufacturing, translational R&D and commercial operations. BioNTech distributes products and clinical supplies worldwide through direct commercialization in select markets and partnerships with global collaborators and distributors.
Summary from filing dated 2025-03-10
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-1.14B |
| Total assets | $21.99B |
| Total liabilities | $2.76B |
| Stockholders' equity | — |
| Operating cash flow | — |